Abstract Although cisplatin is considered as an effective anti-cancer agent, it has shown limitations and may produce toxicity in patients. Therefore, we synthesized two cis-dichlorideplatinum(II) compounds (13 and 14) composed of meta-and para-N,N-diphenyl pyridineamine ligands through a reaction of the amine precursors and PtCl 2 with respective yields of 16 and 47 %. We hypothesized that compounds 13 and 14, with lipophilic ligands, should transport efficiently in cancer cells and demonstrate more effectiveness than cisplatin. When tested for biological activity, compounds 13 and 14 were found to inhibit the growth of MCF 7 and MDA-MB-231 cells (IC 50s 1 ± 0.4 lM and 1 ± 0.2 lM for 13 and 14, respectively, and IC 50 7.5 ± 1.3 lM for compound 13 and 1 ± 0.3 lM for compound 14). Incidentally, these doses were found to be lower than cisplatin doses (IC 50 5 ± 0.7 lM for MCF 7 and 10 ± 1.1 lM for MDA-MB-231). Similar to cisplatin, 13 and 14 interacted with DNA and induced apoptosis. However, unlike cisplatin, they blocked the migration of MDA-MB-231 cells suggesting that in addition to apoptotic and DNA-binding capabilities, these compounds are useful in blocking the metastatic migration of breast cancer cells. To delineate the mechanism of action, computer-aided analyses (DFT calculations) were conducted for compound 13. Results indicate that in vivo, the pyridineamine ligands are likely to dissociate from the complex, forming a platinum DNA adduct with antiproliferative activity. These results suggest that complexes 13 and 14 hold promise as potential anti-cancer agents. 
, photo-and electroluminescence [4] [5] [6] [7] [8] [9] [10] [11] , and charge-transfer polymers [12] [13] [14] . Since the discovery of anti-cancer activity by a variety of platinum complexes and, in particular, cisplatin 1 ( Fig. 1 ) [15, 16] , these types of compounds have been tested on a wide variety of cancer cells and tissues as potential cancertreatment agents [17] [18] [19] [20] [21] [22] [23] [24] [25] . Cisplatin, which is widely used in cancer treatment, is restricted by its limited activity to a narrow range of tumors as well as by severe side effects, such as nephrotoxicity, neurotoxicity, and myelotoxicity [19] . Although treating cancer patients with cisplatin and a combination of other cancer drugs is popular and initially effective, the developed resistance of cancer cells to cisplatin makes this method inefficient [26] . Thus, there is an urgent need to develop effective anti-cancer drugs that will produce minimum side effects. Among the various designs, metal complexes composed of aromatic appendages are reported to exhibit a dualfunction mode of action in which DNA binding occurs through coordination between the metal center and the DNA base pairs, along with p-p aromatic intercalations between the double helix and the aromatic components of the drug [21] [22] [23] [24] . Complexes composed of phenanthroline, such as 56MESS 2, phenanthrenequinone 3, and pyridin-2-yl-acetate 4 ( Fig. 1 ) are reported to function through an intercalation mechanism only; however, these are still potent against cancer cells as compared to their non-intercalating analogs [21, 27] . Recently, trans-type complexes, such as 5a and 5b have also been reported; however, the activity of trans-analogs has been studied to a lesser extent [17, 21] . Substituted diphenylethylenediamine complexes reported by Schonenberger have also been studied, for which hydroxyl and fluoro-substituted analog 6a exhibited lesser activity than the less hindered fluoro-substituted complex 6b, for which the authors argue a hydrogenbonding effect within the DNA and Pt complex adduct [28] [29] [30] [31] [32] [33] [34] . Monofunctional derivatives of cisplatin containing only one leaving group have also been explored as potential anti-cancer agents, 7a-7h ( Fig. 1 ) [35] , which are reported to bind to DNA in a monodentate fashion, unlike the mode of action reported for cisplatin, which forms links between adjacent guanosine residues in DNA [35] .
These compounds were designed to establish a structure-activity relation (SAR) by varying the size of the Fig. 1 Structures of explored anti-tumor platinum complexes pyridine ligand. However, no SAR could be established, because out of the complexes with the larger ligands, 7f-h, only 7g exhibited better activity (up to 40 times greater) than cisplatin, whereas complexes 7f and 7h demonstrated lesser activity. Of the complexes with smaller ligands, 7b is undergoing clinical trials, but the remaining complexes containing small ligands have not demonstrated efficient applications as cancer agents [35] . On the other hand, pyriplatin (7a) has been proven to work efficiently against certain tumors in mice [36, 37] .
Other designs include asymmetric-cyclometalated diamine 8 and ammonia-pyridyl complex 9 ( Fig. 1) [38, 39] . Complex 8 was reported to exhibit high anti-tumor efficiency against cisplatin-resistant mouse sarcoma in 180 cell lines. As for complex 9, substitution of one amine group by a heterocyclic ligand did not increase binding of the complex to DNA but instead lowered the activity of the compound for both sensitive and resistant cell lines. Interestingly, pyridineamine complexes analogous to those reported in this work (10-12) that do not contain phenyl substituents on the amine groups have also been reported. However, these complexes exhibit low activity against sarcoma 180 [25] , which leads to an interesting comparison with the compounds reported in this work and the potential benefit of molecules containing flexible organic ligands in anti-tumor activity.
In this article, we report the synthesis and characterization of complexes 13 and 14 ( Fig. 2 ) composed of N,Ndiphenyl pyridineamine ligands (15 and 16) , and demonstrate their anti-proliferative effects on breast cancer cells. We anticipate that the lipophilicity of the aromatic ligands may enhance cell permeation, as has been reported for similar platinum complexes [21, 25] , leading to enhanced activity. The observed anti-proliferative effects of 13 and 14 against MCF 7 and MDA-MB-231 support this prediction by demonstrating improved activity when compared with cisplatin. The novelty of the compounds lies in the structure of the organic ligands, which, contrary to the majority of the aromatic ligands explored in this area, provide a flexible complex that is highly lipophilic-a characteristic that promotes cell permeation. Contrary to typical designs for anti-tumor drugs, computational work suggests that in these molecules, the pyridyl ligands are more labile than the chlorides by about 4.5 kcal/mol and therefore may exhibit a different mechanism of action than cisplatin.
Materials and methods

Materials
All materials were used as received, unless specified.
[para-amino pyridine, 18-crown-6, platinum chloride (Sigma Aldrich), bromobenzene, copper iodide (Alfa Aesar), meta-amino pyridine (TCI America), hexanes (Macron Chemicals), diethyl ether, acetone, potassium carbonate (BDH), dichloromethane (EMD)]. Cisplatin (Strem Chemicals Inc., Newburyport, MA), propidium iodide (Beckman Coulter, Miami, FL, USA), penicillin/ streptomycin (Hyclone, Logan, UT, USA), Roswell Park Memorial Institute medium (RPMI-1640) and Dulbecco's modified Eagle medium (DMEM) were purchased from Gibco Invitrogen, Carlsbad, CA, and fetal bovine serum from Atlanta Biologicals, Lawrence, GA. NucView 488 Caspase-3/7 substrate (Biotium, Hayward, CA, USA), JC-1 fluorescent dye (MitoProbe; Life Technologies, Grand Island, NY, USA). Reaction solvents were dried over 4 Å molecular sieves (EMD) at least 24 h before use, or collected from a solvent purification system (MBRAUN). Reactions were monitored by silica gel thin layer chromatography using silica gel plates 60 F 254 (EMD) and visualized under ultraviolet light (254 nm). Compound purifications were performed using 63-200 mesh 60 Å silica gel (EMD). Moisture-sensitive reactions were carried out in oven-dried glassware under a nitrogen atmosphere, using standard Schlenk techniques.
1 H and 13 C NMR spectra were obtained with a JEOL 600 MHz spectrometer. Chemical shifts were recorded relative to residual proton or carbon resonances in deuterated solvents. Infrared (IR) spectra were obtained with a Perkin-Elmer FTIR spectrum-100 spectrometer (equipped with ATR accessory) as neat solids. Melting points (Mp) were measured on a Mel-Temp melting point apparatus (1002D), and are uncorrected. Mass spectra (MS) were acquired by electrospray ionization (ESI) measured on a JEOL AccuTOF JMS-T100LC 
Preparation of the platinum complexes solutions
Fresh stock solutions (10 mM) of compounds 13 and 14 were prepared in dimethyl sulfoxide (DMSO), followed by sonication in a water-bath sonicator for 1 min at room temperature, power level 9. Cisplatin was used as a positive control and was also prepared freshly in DMSO (stock concentration, 16.6 mM).
Culture of human breast cancer cells
Breast cancer cells MCF 7 and MDA-MB-231 were cultured in RPMI-1640 and DMEM/Ham's F-12 media, supplemented with 10 % fetal bovine serum and 1 % penicillin/streptomycin [41] . The cancer cells were grown in a humidified atmosphere (95 % air and 5 % CO 2 ) until they reached *90 % confluency, then the confluent cells were trypsinized (0.25 % Trypsin-EDTA, Hyclone), harvested by centrifugation, and grown in tissue-culture flasks.
Cell viability assay
Cells were harvested, plated on a 12-well plate (*1 9 10 5 cells per well) and incubated for 24 h at 37°C. Various amounts (0, 1, 10, 20, and 50 lM) of compounds 13, 14, or cisplatin were added and the incubations were continued for an additional 24 h at 37°C before harvesting the cells by trypsinization followed by centrifugation (93,000 rpm, 5 min). The cells were counted under the microscope using hemocytometer to determine the viabilities of control and treated cells. To evaluate the effect of cisplatin, cells were treated for 24 h as reported by other investigators [42, 43] . The effect of ligands 15 and 16 were also tested on the cell viability. For this, cells were plated and treated as described above. Different concentrations of ligand 15 (0.5, 1, and 1.5 lM for MCF 7 cells and 3.5, 7.5, and 10 lM for MDA-MB-231 cells) and ligand 16 (0.5, 1, and 1.5 lM for both MCF 7 and MDA-MB-231 cells) were used. The concentrations were chosen on the basis of the IC 50s for compounds 13 and 14. The cells were incubated for 24 h at 37°C and were counted under the microscope using hemocytometer.
Examination of phosphatidylserine (PS) externalization in cell membranes
Cells were plated in 24-well microplates at a density of 10,000 cells/well with 1 ml of growth media and incubated for 24 h. Next, MCF 7 cells were treated with 1 lM concentrations of compounds 13 or 14; whereas, MDA-MB-231 cells were treated with 7.5 and 1 lM concentrations of compounds 13 and 14, respectively. Cisplatin was added at 5 lM concentration to MCF 7 and at 10 lM concentration to MDA-MB-231 cells. Cells were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) and analyzed by a Cytomics FC 500 flow cytometer [44] . For each sample, data from 10,000 events were recorded [45] , and subsequently analyzed. Cells negative for both PI and annexin V were considered live cells; PI-negative, annexin V-positive staining cells were early apoptotic cells; PI-positive, annexin V-positive staining cells were cells in late stages of apoptosis; and PIpositive, annexin V-negative staining cells were necrotic [46] [47] [48] . The percentage of apoptotic cells was expressed as the sum of both early and late phases of apoptosis.
Analysis of mitochondrial membrane potential
The mitochondria membrane potential was analyzed by using 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1), a lipophilic cationic aggregate-forming fluorescent dye, following the manufacturer's protocol, as a fluorescence probe. Human breast cancer cell lines were seeded into a 24-well plate at 100,000 cells/well in 1 ml culture media and allowed to attach overnight. The MCF 7 and MDA-MB-231 cells were treated with 1 and 7.5 lM concentrations of compound 13, 1 lM concentrations of compound 14, as well as 5 and 10 lM concentrations of cisplatin, respectively, and incubated for 8 h [49] . Subsequently, cells were stained with a 2 lM concentration of JC-1, following the manufacturer's protocol. Changes of the mitochondria DWm were monitored in a live-cell modality via cytofluorimetric analysis. Polarized mitochondria allow JC-1 aggregation as indicated by the emission of red signals, whereas depolarized mitochondria allows the formation of JC-1 monomer, which can be detected by green signals. Cisplatin was included as a reference drug. A proton ionophore, carbonyl cyanide 3-chlorophenylhydrazone (CCCP; 50 lM) was used as a positive control of mitochondrial DWm depolarizer. In addition, solvent, 0.2 % v/v DMSO, and untreated controls were concomitantly analyzed. Data acquisition and analysis was performed with CXP software.
Cell migration assay
Migration of breast cancer cells was tested as described by Cao et al. [50] . Briefly, *1 9 10 6 cells were plated in each well of a 6-well plate and cultured as a monolayer to confluence overnight in RPMI-1640 and DMEM for MCF 7 and MDA-MB-231, respectively, prior to serum starvation (5 % fetal bovine serum) for 24 h. Next day, the monolayers were wounded by scratching with a sterile 10 ll pipette tip [51] and treated with compounds 13, 14, or cisplatin for 24 h. The concentrations of the compounds used were their respective IC 50 values. The images of the cells that had migrated between wounded regions were captured at 0 and 24 h using a Nikon TMS microscope equipped with a Nikon F-601 camera. The number of cells that migrated into the wounded area was counted. All experiments were carried out in triplicate.
DNA mobility-shift assay
Interaction between DNA and any given molecule forming a DNA complex is investigated by monitoring the retardation of DNA migration using agarose gel electrophoresis [52] . Intercalation, or binding, of a chemical compound to DNA molecules results in decreased mobility of complexes after electrophoresis. Additionally, by using this approach, it is possible to evidence if there is any deleterious effect, causing direct plasmid DNA degradation or fragmentation by a given chemical compound. The reaction mixture in phosphate buffered saline (PBS) (total volume 10 ll) containing the platinum complexes (final concentration 1 mM) and plasmid DNA (500 ng) were incubated for 30 min at 37°C. The reaction was stopped by adding 2 ll of 69 gel loading buffer and placing the reaction tubes on ice. The samples were analyzed by using 1 % (w/v) agarose gels dissolved in TAE buffer (0.04 M Tris base, 0.04 M acetate, and 0.001 M ethylenediaminetetraacetic acid, EDTA). Ethidium bromide, a fluorescence agent, was used in the agarose gel during electrophoresis (0.5 lg/ml) for staining DNA. DNA was visualized under UV-light trans-illuminator. Cisplatin, and the widely used DNA intercalator, 4 0 ,6-diamidino-2-phenylindole (DAPI), were included as positive controls. Nystatin (1 mM) was included as a negative control.
Statistical analyses
All results were expressed as the mean ± SD, and statistical analysis was performed using Microsoft Excel (2007) software. Statistical analyses were performed using twotailed Student's t test. Differences were considered significant when P \ 0.05.
Computational analyses
Density functional theory (DFT) [53, 54] calculations were performed with the hybrid Becke-3 [55] [56] [57] parameter exchange functional and the Lee et al. [58] nonlocal correlation functional (B3LYP) as implemented in the Gaussian 09 program suite [59] . Double-f-quality basis sets (D95) [60] , were used on nonmetal atoms (carbon, nitrogen, and hydrogen). An Effective Core Potential (ECP) [61, 62] representing the 1s2s2p3s3p3d core was used for the platinum atoms along with the associated double-f basis set (LANL2DZ). The convergence criterion for the self-consistent field cycles on all calculations was increased from the default value of 10 -3 to 10 -8 , in order to increase the statistical confidence and accuracy of the wavefunctions. Geometry optimization calculations were found to be minima in the potential energy surface as evidenced by the lack of imaginary vibrations in the frequency calculations. Transition state searches were performed using the synchronous transit-guided quasi-Newton (STQN) method [63] with the input of three initial geometries representing the reactants, products, and transition state guess (QST3) as implemented in Gaussian 09. All transition state geometries were identified as saddle-points in a potential energy surface by the location of one (and only one) imaginary frequency. The normal vibration mode of this imaginary frequency was germane to the studied mechanism of ligand substitution by a DMSO ligand. The transition state that describes the substitution nucleophilic bimolecular (SN2) displacement of chloride shows an imaginary mode of vibration 65i cm -1 , while the pyridineamine displacement mechanism showed a respective frequency of 89i cm -1 . All the calculations were performed on a full-atom model of 13 with no simplifications. A polarized-continuum model [64, 65] with DMSO-solvent parameters, as implemented in the Gaussian 09 suite, was utilized on all calculations. All calculations were performed in a 44-processor Power Wolf PSSC supercomputer cluster running Linux Red Hat 4.1.2-54 located at the University of Texas at El Paso.
Results and discussion
Synthesis of ligands
Known ligands 15 and 16 were prepared under Ullmann conditions in 53 and 81 % yields, respectively, through a coupling reaction of the corresponding pyridineamines with bromobenzene by refluxing in the presence of CuI, K 2 CO 3 , and 18-crown-6 under a nitrogen atmosphere. A representative reaction for ligand 15 is depicted in Scheme 1 [66] [67] [68] [69] [70] [71] [72] [73] . These are improved conditions for the synthesis of these ligands, which have been reported in 35 and 42 % yields, respectively, as elimination products of 3-bromopyridines under strongly basic conditions [74] .
Synthesis of complexes
Target complexes 13 and 14 were prepared following reported conditions for pyridine coordination complexes, as depicted in Scheme 1 for complex 13, by dissolving the ligand in benzene, followed by addition of PtCl 2 , and subsequently heating to 80°C in a pressure vessel for 12-15 h [1] [2] [3] 75] . Under these conditions, both cis-and trans-products are produced, however, due to the structural comparability to cisplatin, the current biological studies will only focus on the cis-analogs.
Both complexes were characterized by 1 H and 13 C nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, and electrospray mass spectrometry (ES-MS). Complex 13 was further characterized by X-ray crystallography, as described below and in the Experimental section. The complexes are robust, exhibiting no decomposition in solution for months, and melting points in the range of 285-300°C with decomposition.
X-ray crystallography
Chiral complex meta-cis 13 crystallized from CH 2 Cl 2 as a racemate in the centrosymmetric spatial group P2 1 /n with an inversion center that relates both isomers (Fig. 3) (crystallographic parameters and selected bond lengths in Tables 1, 2 , respectively). The tilt of the pyridine groups with respect to the mean plane of the square planar system is 45.7°for the ring with N1, and 53.2°for that of N3. On the other hand, the dihedral angle between the two amino groups, N2 and N4, is 55.1°with respect to each ligand plane. Both ligands are planar at the central nitrogen, with dihedral angles of 31.3°(C2), 62.4°(C6), and 37.7°(C12) on the ligand containing N1. As for the ligand containing N3, the dihedral angles are 24.4°(C20), 59 .7°(C24), and 49.9°(C30). This complex also exhibits HÁÁÁCl interactions between Cl1ÁÁÁH27 (2.89 Å ), Cl2ÁÁÁH15 (2.87 Å ) and Cl2ÁÁÁH34 (2.91 Å ), as well as two-dimensional (2-D) sheets along with HÁÁÁp interactions between H4 and C12 (2.86 Å ), which contribute to the 2-D arrangement.
Attempts to grow X-ray-quality crystals of para-cis 14 from CH 2 Cl 2 , CHCl 3 , and mixtures of these solvents with hexanes, diethyl ether, and benzene, as well as diffusion methods using these solvents, produced very small crystals, from which the unit cell was solved, and determined to be equivalent to the unit cell of meta-cis 13.
Compounds 13 and 14 inhibit the growth of breast cancer cells in culture
To evaluate potential biological activities, compounds 13 and 14 were tested on MCF 7 and MDA-MB-231 cells and their respective half-maximal cytotoxic concentrations (IC 50s ) are shown in Table 3 . While the IC 50s of compound 13 for MCF 7 and MDA-MB-231 are 1 ± 0.4 and 7.5 ± 1.3 lM, compound 14 inhibits MCF 7 at 1 ± 0.2 lM and MDA-MB-231 at 1 ± 0.3 lM concentration. Our results indicate that the activity of these two compounds is attributed to the flexible nature of the aromatic ligands. This conclusion is based on the low activity reported for analogous aminopyridine complexes of Pt(II) dichloride, 10-12 [25] (Fig. 1) , which lack the two phenyl 42, 43, 76 ] and the results demonstrate that IC 50s of cisplatin against MCF 7 and MDA-MB-231 cells are 5 ± 0.7 lM and 10 ± 1.1 lM, respectively, which are higher than compounds 13 and 14 (Table 3) . In a related experiment, we tested the effects of free ligands 15 and 16 (see the ''Methods'' section) and no changes in viability were observed, indicating that anti-proliferative activities of compounds 13 and 14 are not due to their respective free ligands (data not shown).
Because many cytotoxic anti-cancer agents exert their effects by inducing apoptosis [77] , we investigated whether compounds 13 and 14 also cause apoptosis in these two breast cancer cells. Therefore, control and Pt complexestreated cells were labeled with Annexin V-FITC and PI and analyzed in live-cell modality by flow cytometry (Fig. 4) , as described in the Experimental section. Again, cisplatin The percentages of viable, apoptotic, and necrotic cells were determined from the relative intensities of the Annexin V and PI staining. The results shown are mean ± SD (n = 3), indicating a significant difference from the control (DMSO-treated) group (*P B 0.05; **P B 0.01; ***P B 0.001; ****P B 0.0001) as determined by the Student's t test was used as a positive control; since it has been reported to form DNA adducts that lead to cellular apoptosis [77] . We found that compounds 13 and 14 inhibit the growth of breast cancer cells by inducing apoptosis, results that are similar to cisplatin, although the concentration of cisplatin used is higher (IC 50s for cisplatin is 5 ± 0.7 lM for MCF 7 and 10 ± 1.1 lM against MDA-MB-231 cells) than compounds 13 and 14 (Fig. 4) . Interestingly, no significant increase in necrosis by these Pt compounds was noted. Figure 4b depicts the quantitative assessment of apoptosis presented in Fig. 4a , which indicate that all these compounds increase the number of apoptotic cells *twofold in MCF 7 and *3-4 fold in MDA-MB-231 cells, compared with respective control cells (i.e., MCF 7 and MDA-MB-231). At this point it is not clear why MDA-MB-231 cells are more responsive to the Pt complexes than MCF 7 cells. These differences could be, however, due to the genetic and epigenetic makeup of the two different cell types.
Mitochondrial depolarization assay
Our next goal was to determine, at least in part, the mechanism by which these Pt complexes can induce apoptosis [78] . MDA-MB-231 cells were exposed for 8 h to compounds 13, 14 and cisplatin, stained with JC-1 and monitored via flow cytometer in a live-cell fashion, as described in the Experimental section. Findings displayed that mitochondrial membrane potential (Dwm) in MDA-MB-231 cells is altered by compound 13 as judged by an increase in the percentage of depolarized cells, demonstrative of mitochondrial DWm perturbation (Fig. 5a, b) . Also, a shift in the chromatic signal from red to green was detected in CCCP-treated cells, which were used as a positive control. In contrast, cells exposed to compound 14 and cisplatin mirrored the untreated cells, as evidenced by the absence of green signal, an indication of unaltered Dwm. These results suggest that compound 13, but not 14 and cisplatin, utilize the mitochondrial-dependent apoptotic intrinsic pathway to induce cell death in MDA-MB-231 cells (Fig. 5) .
Wound-healing assays
Migration of cancer cells is associated with the activity of extracellular-matrix ligands and signals necessary for locomotion. Migration facilitates cancer cells by invading the surrounding tissue and colonizing to a new site to form a In a, representative flow cytometric dot plots (i-v) used to quantify the distribution of cells emitting green signal, due to depolarized mitochondria (lower section on the plots). The color of dots (events) on the plots shows a density gradient transitioning from blue (low) to red (high) gradient. CCCP (50 lM) was used as a positive control to assess the mitochondrial DWm. Approximately 10,000 events were acquired and analyzed. b (bar graph) Represents the results of mitochondria membrane depolarization that were obtained from the flow cytograms shown in a. Results shown are the mean of three independent measurements. Analysis using the two-tailed Student's paired t test comparing compound 13-treated cells with DMSOsolvent controls gave P \ 0.001 (***) tumor [79, 80] . Here, we asked if these Pt complexes blocked the migration of MDA-MB-231 cells. We used wound-healing assays, which are standard procedures in monitoring cell migration and angiogenesis in a laboratory setting [51] . The effect of compounds 13, 14, and cisplatin were examined on the migration of MDA-MB-231. Results show that both 13 and 14 are effective in blocking cell migration in culture, and are more potent than cisplatin.
Interaction with DNA Usually, cytotoxic agents induce cell death either by interfering with the cell-cycle regulation or by inducing apoptosis [81] . Cumulative evidence suggests that cisplatin can cause cell death by first binding with DNA followed by activating the signaling pathways that lead to apoptosis [82] . Therefore, in the current study, we investigated if compounds 13 and 14 could interact with plasmid DNA forming heavier complexes, similar to cisplatin. The binding ability of these compounds was determined by mixing them with plasmid DNA followed by the mobility-shift assay on agarose gels. Compounds 13 and 14 showed shifts as compared with the control plasmid DNA alone and a cholesterol-binding drug, nystatin, which was used as a negative control ( Figure S1 in Supporting Information). The shifts caused by compounds 13 and 14 are comparable with the changes (shifts) caused by DAPI, a DNA intercalating dye, and cisplatin, which binds to two consecutive guanine bases within DNA. Interestingly, it was observed that the plasmid DNA incubated with compound 14 consistently showed a band with low-fluorescence intensity, which could be due to the reason that compound 14 is already occupying to some extent the preferred interaction site of ethidium bromide; used to visualize plasmid DNA under UV light.
Computational modeling of the substitution reaction 1 H NMR experiments were carried out to determine complex stability in solution and to prove the proposed loss of ligands experimentally. However, after many days, the 1 H NMR spectra show a mixture of signals representing the initial complex, the free ligand, as well as other signals that we interpret as dissociation products, making a straightforward analysis by 1 H NMR inconclusive. Therefore, we utilized density functional theory calculations on an allatom model of 13 in order to test the mechanistic pathway of substitution of the pyridineamine vs. chloride ligands bound to the platinum center by a DMSO-solvent molecule. Our calculations were based on a model that mimics the DMSO-solvent effect utilizing a polarized-continuum model (see computational details). In order to measure the activation barrier of SN2 ligand substitution, we performed a transition state search for two potential mechanistic pathways: one in which a chloride ligand is displaced by an incoming DMSO molecule and another in which the pyridineamine ligand is displaced. We were able to find two appropriate transition state geometries for each case that allowed us to measure the activation energy barrier of each mechanism. Figure 7 shows the potential energy surface for both chloride and pyridineamine substitution. The geometry of the complex used to model the substitution reactions was based on the X-ray structural parameters of complex 13. The first pathway described by SN2 substitution of the pyridineamine by a DMSO-solvent molecule approaching the platinum center yields an activation barrier of 20.7 kcal/mol, whereas the chloride-leaving mechanism required 25.2 kcal/mol. This suggests that under the experimental conditions, pyridineamine substitution by DMSO from the platinum center is to some extent more favorable compared with loss of chlorides.
Conclusions
Development of new anti-cancer chemotherapies is a constant endeavor in the field of medicinal chemistry. In this context, the design and development of platinum-based complexes with anti-cancer activities (like cisplatin) are especially interesting and useful. Therefore, in the current study, two cis-isomers of platinum(II) dichloride complexes composed of meta-and para-N,N-diphenyl pyridineamine derivatives (13 and 14) were prepared by initial synthesis of organic ligands 15 and 16 through copper-catalyzed reaction conditions, followed by coordination of the pyridine ligands with platinum dichloride. Furthermore, these complexes were found to be effective in blocking the growth and in inducing apoptosis in MCF 7 and MDA-MB-231. In addition, our findings demonstrate that compounds 13 and 14 also inhibit the migration of MDA-MB-231 cells possibly by affecting cytoskeletal organization membrane and vesicle flow, and cell polarity, as well as decreasing the levels of metabolic energy (ATP). The DNA-shift assay indicates that compounds 13 and 14 interact with DNA strands and produce platinum-DNA adducts, like cisplatin [82] . To the best of our knowledge, this is the first example of platinum(II) complexes composed of pyridine derivatives of triphenylamine that are tested for anti-cancer activity. Our results demonstrate a biological activity that is unique to complexes containing this type of pyridineamine derivatives, which provides these molecules with anti-cancer activity that is absent in structurally similar Pt(II) dichloride complexes, such as 10-12 ( Fig. 1) [25] . We speculate that both compounds (13 and 14) have potential as anti-breast cancer drugs and provide rational insight for its further evaluation in animal models. 
